v3.26.1
Segments Reporting
 3 Months Ended
Mar. 31, 2026
Segments Reporting [Abstract]  
SEGMENTS REPORTING

NOTE 8– SEGMENTS REPORTING

 

The Company operates as a single operating segment focused on development of novel antimicrobial therapies. As the CODM, our Chief Executive Officer manages our company, reviews operating results, assesses performance and allocates resources on an aggregate basis using total assets and actual expenses compared to net loss. Please refer to the condensed financial statements for further information related to these measures of segment performance.

 

In addition to total assets and actual expenses, the CODM regularly receives disaggregated information regarding research and development expenses, general and administrative expenses, and other segment expenses. Other segment expenses include depreciation and interest expense and are presented net of interest income and other income.

 

The following tables present the significant expense categories reviewed by the CODM:

 

   For the Three Months Ended
March 31,		 
   2026   2025 
Research and Development        
Personnel  $162,784   $142,624 
Clinical and preclinical activities   15,733    23,449 
Other   3,630    3,630 
Total research and development   182,147    169,703 
         
General and Administrative        
Personnel   146,840    72,127 
Professional services   427,515    201,488 
Corporate expenses   92,073    60,532 
Facility costs   37,016    37,600 
Total general and administrative   703,444    371,747 
           
Other Segment (Income) Expenses   37,700    (1,833)
           
Net Loss  $923,291   $539,617